Evidence map›Paper›PMID 42757248›Full record

ArticleFrontiers in oncology2026

Correction: MUS81 participates in the progression of serous ovarian cancer associated with dysfunctional DNA repair system.

Renquan Lu, Suhong Xie, Yanchun Wang, Hui Zheng, Hongqin Zhang, Minjie Deng, Weizhong Shi, Ailing Zhong, Miaomiao Chen, Meiqin Zhang and 3 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Renquan LuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Suhong XieDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanchun WangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Hui ZhengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Hongqin ZhangDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Minjie DengDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Weizhong ShiDepartment of Clinical Laboratory, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Ailing ZhongDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Miaomiao ChenDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Meiqin ZhangDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaofeng XuDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.
Masood A ShammasDepartment of Medical Oncology, Dana Farber (Harvard) Cancer Institute, Boston, MA, United States.
Lin GuoDepartment of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.3389/fonc.2019.01189.].

Indexed as

chemotherapyDNA damagehomologous recombination (HR)MUS81ovarian cancer

Identifiers

PMID42757248
PMCPMC13584860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.